Altre lingue Edesa Biotech, Inc.

Azioni

Tempo differito Nasdaq Altri mercati azionari 19:27:08 26/04/2024			Variaz. 5gg	Var. 1 gen.
4,42 ^USD	-1,09%		-0,68%	-3,28%

05/03	I migliori guadagni del mercato premarket	MT
09/02	Edesa Biotech, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 dicembre 2023	CI

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference	12/04
Edesa Biotech to Participate in Barclays Global Healthcare Conference	08/03
Top Premarket Gainers	05/03
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	09/02
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	15/12
Top Premarket Decliners	13/12
Top Premarket Gainers	22/11
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	20/11
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug	26/10/23
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	25/10/23
Top Premarket Decliners	13/10/23
Sector Update: Health Care Stocks Decline in Late Afternoon	12/10/23
Sector Update: Health Care	12/10/23
Top Midday Gainers	12/10/23
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	12/10/23
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	10/10/23
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate	29/09/23
Edesa Biotech, Inc. Publishes Phase 2 Substudy Results of ARDS Drug Candidate	28/09/23
Edesa Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	09/08/23
Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens	28/06/23

Non ci sono risultati per questa ricerca